

## Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer

Teru Hideshima<sup>1</sup>, Ralph Mazitschek<sup>2</sup>, Jun Qi<sup>1</sup>, Naoya Mimura<sup>1,5</sup>, Jen-Chieh Tseng<sup>3,6</sup>, Andrew L. Kung<sup>3,4,7</sup>, James E. Bradner<sup>1,8</sup> and Kenneth C. Anderson<sup>1</sup>

<sup>1</sup>Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

<sup>2</sup>Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

<sup>3</sup>Lurie Family Imaging Center, Dana-Farber Cancer Institute, Boston, MA, USA

<sup>4</sup>Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Boston, MA, USA

<sup>5</sup>Department of Hematology, Chiba University Hospital, Chiba, Japan

<sup>6</sup>PerkinElmer Inc., Hopkinton, MA, USA

<sup>7</sup>Memorial Sloan Kettering Cancer Center, New York, NY, USA

<sup>8</sup>Novartis Institutes for BioMedical Research, Cambridge, MA, USA

**Published:** August 17, 2021

**Copyright:** © 2021 Hideshima et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The CONFLICTS OF INTERESTS section has been updated as shown below:

### CONFLICTS OF INTEREST

K.C. Anderson is on the advisory board of Celgene, Gilead, Millennium and Bristol Myers Squibb; and is a scientific founder with financial interest in Acetylon, Oncopep and C4 Therapeutics. JB is a scientific founder with financial interest in Acetylon.

Original article: Oncotarget. 2017; 8:80109–80123. <https://doi.org/10.18632/oncotarget.19019>